96 related articles for article (PubMed ID: 16093435)
1. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis.
D'Andrea MR; Mei JM; Tuman RW; Galemmo RA; Johnson DL
Mol Cancer Ther; 2005 Aug; 4(8):1198-204. PubMed ID: 16093435
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of phospholipase Cgamma1 on tyrosine residue 783 by platelet-derived growth factor regulates reorganization of the cytoskeleton.
Yu H; Fukami K; Itoh T; Takenawa T
Exp Cell Res; 1998 Aug; 243(1):113-22. PubMed ID: 9716455
[TBL] [Abstract][Full Text] [Related]
3. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
4. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of platelet-derived growth factor receptor tyrosine kinase and downstream signaling pathways by Compound C.
Kwon HJ; Kim GE; Lee YT; Jeong MS; Kang I; Yang D; Yeo EJ
Cell Signal; 2013 Apr; 25(4):883-97. PubMed ID: 23277201
[TBL] [Abstract][Full Text] [Related]
6. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.
Ho CY; Ludovici DW; Maharoof US; Mei J; Sechler JL; Tuman RW; Strobel ED; Andraka L; Yen HK; Leo G; Li J; Almond H; Lu H; DeVine A; Tominovich RM; Baker J; Emanuel S; Gruninger RH; Middleton SA; Johnson DL; Galemmo RA
J Med Chem; 2005 Dec; 48(26):8163-73. PubMed ID: 16366598
[TBL] [Abstract][Full Text] [Related]
7. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS; Jovcheva E; Mevellec L; Vialard J; De Lange D; Verhulst T; Paulussen C; Van De Ven K; King P; Freyne E; Rees DC; Squires M; Saxty G; Page M; Murray CW; Gilissen R; Ward G; Thompson NT; Newell DR; Cheng N; Xie L; Yang J; Platero SJ; Karkera JD; Moy C; Angibaud P; Laquerre S; Lorenzi MV
Mol Cancer Ther; 2017 Jun; 16(6):1010-1020. PubMed ID: 28341788
[TBL] [Abstract][Full Text] [Related]
9. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor stimulates sodium-dependent Pi transport in osteoblastic cells via phospholipase Cgamma and phosphatidylinositol 3' -kinase.
Zhen X; Bonjour JP; Caverzasio J
J Bone Miner Res; 1997 Jan; 12(1):36-44. PubMed ID: 9240723
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
[TBL] [Abstract][Full Text] [Related]
13. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor-induced activation of sphingosine kinase requires phosphorylation of the PDGF receptor tyrosine residue responsible for binding of PLCgamma.
Olivera A; Edsall L; Poulton S; Kazlauskas A; Spiegel S
FASEB J; 1999 Sep; 13(12):1593-600. PubMed ID: 10463951
[TBL] [Abstract][Full Text] [Related]
15. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
[TBL] [Abstract][Full Text] [Related]
16. Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro.
Meisenhelder J; Suh PG; Rhee SG; Hunter T
Cell; 1989 Jun; 57(7):1109-22. PubMed ID: 2472219
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of PDGF receptor tyrosine kinase activity from PDGF-mediated inhibition of gap junctional communication.
Pelletier DB; Boynton AL
J Cell Physiol; 1994 Mar; 158(3):427-34. PubMed ID: 8126067
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of phospholipase Cgamma1 activity during EGF-induced proliferation of corneal epithelial cells: effect of phosphoinositide-3 kinase.
Islam M; Akhtar RA
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1472-8. PubMed ID: 11381049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]